Optimum Video Q&A: Getting to know Renee Aguiar-Lucander
Since taking over as CEO of Calliditas Therapeutics in 2017, Renee Aguiar-Lucander has taken the biotech through an IPO in Stockholm and commenced a pivotal phase 3 trial plus major licensing deals and a secondary fund raise. She has established a US presence, made transformational regulatory milestones, and this month completed a successful upsized US listing on NASDAQ raising USD 90 million. Eleanor Malone, Editor SCRIP Intelligence speaks to Renee about her experiences.
Check out interview HIGHLIGHTS or watch full interview below.